Navigation Links
Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
Date:9/30/2008

e Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from the registration requirements. Micromet, Inc. has agreed to file a registration statement with respect to the shares within 30 calendar days after the closing date. This news release is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933, as amended.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody blinatumomab (MT103/MEDI-538) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung or gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody that targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293
'/>"/>

SOURCE Micromet, Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
2. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
3. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
4. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
5. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
6. Micromet to Present at Two Upcoming Investor Conferences
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
9. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
10. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
11. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Two champions of science, technology, engineering, and ... annual competition for middle and high school students designed ... study. The competition presents students with real-world problems experienced ... Mathematics, and Sciences is a program administered by ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider ... treatment of tinnitus. Patients listen to sound therapy that ... period of weeks to months, their tinnitus volume decreases. , ... Notched Music and Notched White Noise. Now, AudioNotch is pleased ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... the latest wireless accessory to come from ... manufacturer of advanced interoperable communication systems. , ... contains a two-way radio, cellular and satellite technologies, ... integrated power systems and extreme lighting to provide ...
... 2003. GenTel BioSurfaces, Inc., a privately held UWMadison biotechnology ... Burke, Ph.D., to its Scientific Advisory Board. , ,"Tom's ... in grant writing, intellectual property management, and new product ... GenTel in its next stage of growth," said Bryce ...
... the Midwest at places like the Maytag plant in Galesburg, Ill., ... are many experts giving opinions about why these jobs are disappearing. ... for cheaper wages and most stop there with their strategic analysis. ... are so focused on the bottom line. Its a safe bet ...
Cached Biology Technology:Not Just Another Gadget - It's the Gauntlet: The Next Step in Wearable Communications 2GenTel Appoints Burke to its Scientific Advisory Board 2Spend Money to Make Money and Dump Obsolete Tech Strategies 2Spend Money to Make Money and Dump Obsolete Tech Strategies 3Spend Money to Make Money and Dump Obsolete Tech Strategies 4
(Date:4/22/2014)... FL, April 22, 2014 Scientists from the Florida ... a protein complex that plays a critical but previously ... The study, which showed a novel role for a ... in the journal eLife , a publisher supported ... Society and the Wellcome Trust. , "This is a ...
(Date:4/22/2014)... Inspired by the fist-like club of a ... of California, Riverside, in collaboration with University of Southern ... for composite materials that is more impact resistant and ... more we study the club of this tiny crustacean, ... many things we use every day," said David Kisailus, ...
(Date:4/22/2014)... Scientists at the University of Massachusetts Amherst and ... this week report that they have discovered a new ... of the Negro River in the Amazonia State of ... with Adlia Nogueira and Jos Antnio Alves-Gomes of INPA, ... of the journal Proceedings of the Natural Sciences ...
Breaking Biology News(10 mins):Scientists identify critical new protein complex involved in learning and memory 2Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3New electric fish genus and species discovered in Brazil's Rio Negro 2
... A research collaboration led by biologists and neuroscientists at the ... brain that is the cause of cognitive impairment due to ... the cognitive deficits caused by sleep deprivation, such as an ... reducing the concentration of a specific enzyme that builds up ...
... Boston, Mass. -- Millions of children in the United ... from suboptimal levels of vitamin D, according to a large ... Pediatrics , accompanied by an editorial. The study, ... the most up-to-date analysis of vitamin D levels in U.S. ...
... has provided scientists with new insights into how genetic changes ... Wellcome Trust and the Danish Cancer Society, could explain why ... fathers. Mutations can occur in different cells of ... as those which occur in ,germ cells, (those which create ...
Cached Biology News:Fighting sleep, Penn researchers reverse the cognitive impairment caused by sleep deprivation 2Latest analysis confirms suboptimal vitamin D levels in millions of US children 2Testicular tumors may explain why some diseases are more common in children of older fathers 2
... of Cell Cultures (ECACC) in conjunction with ... West of England, Bristol, UK, have produced ... of HER2, oestrogen and progresterone receptor assays. ... of formalin fixed, breast cancer cell lines; ...
... the highly potent TURBO DNase (patent pending) in ... set in DNA removal capabilities. TURBO DNase is ... is much more efficient than wild type DNase ... DNA. TURBO DNase binds DNA substrates 6-fold more ...
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
PP2B-Abeta (C-20)...
Biology Products: